Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directorate Change

18th Dec 2017 07:00

RNS Number : 5735Z
Collagen Solutions PLC
18 December 2017
 

 

 

 

 

December 18, 2017

 

Collagen Solutions Plc

(the "Company" or the "Group")

 

Collagen Solutions Strengthens Board with Non-Executive Appointment

 

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular is pleased to announce the appointment of Chris Brinsmead CBE to the Non-Executive Board.

 

Chris Brinsmead (58) has worked in the Pharmaceutical industry for over thirty years, holding executive leadership roles within ICI and AstraZeneca. He was President of the ABPI from 2008 to 2010. He is currently on the Board of UDG Healthcare plc and The Wesleyan Assurance Society, having previously held Board positions at Domino Printing Sciences plc, Cambian Group plc and Kinapse Ltd. He also chairs two private companies, Proveca Ltd and Bamburgh Capital Ltd. Chris is a Member of Council at Imperial College and an advisor and champion on Life Sciences for the UK Government. He was appointed a CBE in January 2015.

 

Chris Brinsmead holds a BSc in Civil Engineering from Nottingham University and an MSc in Business Science from Manchester Business School.

 

Commenting on this appointment, Jamal Rushdy, CEO of Collagen Solutions said: "We are delighted to have Chris join Collagen Solutions' Board at this pivotal time as we look to significantly expand our core business and launch exciting new proprietary products. His extensive and diverse executive and non-executive experience within the global life sciences arena, including leadership roles in the successful launch of commercial products, will strengthen our strategy and focus on execution for growth."

 

 

Current Directorships

Previous Directorships

UDG Healthcare plc

The Wesleyan Assurance Society

Proveca Limited

Bamburgh Capital Limited

Datapharm Communications Limited

CDB (Meadowside) Limited

Cambian Group Plc

Kinapse Limited

Domino Printing Sciences Plc

 

 

Chris Brinsmead holds 1,731,250 ordinary shares in the capital of the Company.

About Collagen Solutions:

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.

 

 

Enquiries: 

 

Collagen Solutions Plc

Jamal Rushdy, Chief Executive Officer

Via Walbrook

Gill Black, Chief Financial Officer

Lisa Baderoon, Head of Investor Relations

 

Tel: 07721 413 496 or [email protected]

Cenkos Securities plc (Nominated Adviser and Broker)

Stephen Keys

Steve Cox

Tel: 0207 397 8900

 

 

Walbrook PR

Tel: 020 7933 8780 or [email protected]

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFFDFVLRLID

Related Shares:

COS.L
FTSE 100 Latest
Value8,275.66
Change0.00